NEW YORK (GenomeWeb News) – Gentel Biosciences and Eprogen today said that they will collaborate on making whole proteome microarrays for identifying new autoantibody biomarkers.
Eprogen's ProteoSep protein fractionation technology enables whole proteome microarrays to be fabricated from individual cell lines or tissue samples, such as tumor biopsies. The firms will combine that technology with Gentel's protein microarray surface chemistries.
Under the deal, partitioned whole proteome arrays will be offered for fluorescence detection on Gentel's PATH protein microarray slides and chromogenic detection on its APiX Array System. In addition, Gentel said that it will process samples on whole proteome arrays for customers through its Symphony Array Services group.
"The availability of antibodies and recombinant proteins has historically been a bottleneck in the production of protein arrays," explained Gentel President and CEO Alex Vodenlich. "Eprogen's proteome partitioning technology overcomes this bottleneck in a very unique way, and enables fabrication of whole proteome arrays customized for any researcher."
Financial and other terms of the alliance were not disclosed.